Evidence map›Paper›PMID 38454121›Full record

ArticleLeukemia2024

Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.

Melvin E Thomas, Wenqing Qi, Michael P Walsh, Jing Ma, Tamara Westover, Sherif Abdelhamed, Lauren J Ezzell, Chandra Rolle, Emily Xiong, Wojciech Rosikiewicz and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Melvin E ThomasDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.
Wenqing QiDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.
Michael P WalshDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.
Jing MaDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.
Tamara WestoverDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.ORCID 0000-0002-1000-6698
Sherif AbdelhamedDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.
Lauren J EzzellGraduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Chandra RolleDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.
Emily XiongDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.
Wojciech RosikiewiczCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0001-7031-3430
Beisi XuCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-0099-858X
Allister J LoughranCenter for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-6564-5526
Shondra M Pruett-MillerCenter for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-3793-585X
Laura J JankeDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA.
Jeffery M KlcoDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, TN, 38105, USA. Jeffery.klco@stjude.org.ORCID 0000-0003-2961-6960
St. Jude Children's Research Hospital · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
Cellular and functional impact of SAMD9L mutations on hematopoiesis and myelodysplasiaR01HL144653 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KLCO, JEFFERY M · 2019 to 2023
$2.2M
Childhood Hematological Malignancies Training ProgramT32CA236748 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2019 to 2026
$2.0M
The Molecular and Biochemical Function of SAMD9 and SAMD9L in Pediatric MDSF32HL152484 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI THOMAS, MELVIN EDWARD · 2020 to 2022
$155k
NCI NIH HHS P30 CA021765NHLBI NIH HHS F32 HL152484NHLBI NIH HHS R01 HL144653
6 · The paper itself

Abstract

MGA (Max-gene associated) is a dual-specificity transcription factor that negatively regulates MYC-target genes to inhibit proliferation and promote differentiation. Loss-of-function mutations in MGA have been commonly identified in several hematological neoplasms, including acute myeloid leukemia (AML) with RUNX1::RUNX1T1, however, very little is known about the impact of these MGA alterations on normal hematopoiesis or disease progression. We show that representative MGA mutations identified in patient samples abolish protein-protein interactions and transcriptional activity. Using a series of human and mouse model systems, including a newly developed conditional knock-out mouse strain, we demonstrate that loss of MGA results in upregulation of MYC and E2F targets, cell cycle genes, mTOR signaling, and oxidative phosphorylation in normal hematopoietic cells, leading to enhanced proliferation. The loss of MGA induces an open chromatin state at promoters of genes involved in cell cycle and proliferation. RUNX1::RUNX1T1 expression in Mga-deficient murine hematopoietic cells leads to a more aggressive AML with a significantly shortened latency. These data show that MGA regulates multiple pro-proliferative pathways in hematopoietic cells and cooperates with the RUNX1::RUNX1T1 fusion oncoprotein to enhance leukemogenesis.

Indexed as

Core Binding Factor Alpha 2 SubunitDNA-Binding ProteinsLeukemia, Myeloid, AcuteMutationProto-Oncogene ProteinsRUNX1 Translocation Partner 1 ProteinAnimalsBasic Helix-Loop-Helix ProteinsCell ProliferationGene Expression Regulation, LeukemicHumansMiceMice, KnockoutOncogene Proteins, FusionTranscription FactorsBasic Helix-Loop-Helix ProteinsCore Binding Factor Alpha 2 SubunitDNA-Binding ProteinsMGA protein, humanMga protein, mouseMTG8 protein, mouseOncogene Proteins, FusionProto-Oncogene ProteinsRUNX1 protein, humanRUNX1T1 protein, humanRUNX1 Translocation Partner 1 ProteinTranscription Factors

Identifiers

PMID38454121
PMCPMC11073986
OpenAlexW4392546407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.